Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer

2008 ◽  
Vol 18 (5) ◽  
pp. 1007-1012 ◽  
Author(s):  
K. Lin ◽  
D. Ye ◽  
X. Xie
Keyword(s):  
Ovarian Cancer ◽  
Protein Expression ◽  
Clear Cell ◽  
Excision Repair ◽  
Cell Cancer ◽  
Complementation Group ◽  
Serous Ovarian Cancer ◽  
Expression Levels ◽  
Platinum Based Chemotherapy ◽  
Group 1

This study was undertaken to examine whether there is an association between excision repair cross-complementation group 1 (ERCC1) and xeroderma pigmentosum D (XPD) protein expression levels and response to platinum-based chemotherapy in epithelial ovarian cancer (EOC). The study cohort consisted of 91 consecutive patients suffering from stage III or IV disease of primary EOC from 1999 to 2004 at the Women's Hospital, School of Medicine, Zhejiang University. There were 36 sensitive cases of serous ovarian cancer, 27 resistant cases of serous ovarian cancer, 15 cases of clear cell cancer, and 13 cases with serous ovarian cancer receiving neoadjuvant chemotherapy. The ovarian tissue microsections were stained by standard immunohistochemical techniques to show ERCC1 and XPD protein expression levels. In resistance group of serous ovarian cancer, ERCC1 and XPD protein expression levels were significantly higher than those of sensitivity group, and after receiving neoadjuvant chemotherapy, they showed 23% and 32% higher than before. Meanwhile, their levels of clear cell cancer group were significantly higher than serous ovarian cancer group's. Upregulation of ERCC1 and XPD protein expression was associated with resistance process to platinum-based chemotherapy in advanced EOC. This study provided evidence that differences of nucleotide excision repair–related genes expression may have an effect on the observed differences in clinical behavior of EOC

scholarly journals Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy

2009 ◽  
Vol 16 (3) ◽  
pp. 907-918 ◽  
Author(s):  
Cristina L Ronchi ◽  
Silviu Sbiera ◽  
Luitgard Kraus ◽  
Sebastian Wortmann ◽  
Sarah Johanssen ◽  
...  
Keyword(s):  
Protein Expression ◽  
Adrenocortical Carcinoma ◽  
Adrenal Glands ◽  
Excision Repair ◽  
Benign Tumors ◽  
Platinum Compounds ◽  
Platinum Based Chemotherapy ◽  
Cytotoxic Treatment ◽  
Ercc1 Expression ◽  
Group 1

Therapeutic progress in adrenocortical carcinoma (ACC) is severely hampered by its low incidence. Platinum-based chemotherapies are the most effective cytotoxic treatment regimens in ACC but response rates remain <50%. In other tumor entities, expression of excision repair cross complementing group 1 (ERCC1) predicts resistance to platinum compounds. Therefore, we correlated ERCC1 protein expression and clinical outcome. We have retrolectively established adrenal tissue microarrays and analyzed prospectively samples from 163 ACCs, 15 benign adrenal adenomas, and 8 normal adrenal glands by immunohistochemistry for ERCC1 protein expression. Detailed clinical data were available by the German ACC Registry. ERCC1 protein was highly expressed in all normal adrenal glands, 14 benign tumors (93%) and in 75 ACCs (47%). In ACC, no differences in baseline parameters were found between patients with and without ERCC1 expression. Detection of ERCC1 was not correlated with survival in patients who never received platinum-based chemotherapy. In platinum-treated patients (n=45), objective response to platinum compounds was observed in 3/21 patients (14.3%) with high ERCC1 expression and in 7/24 patients (29.2%) with low ERCC1 expression (P=0.23). ERCC1 expression was strongly correlated with overall survival after platinum treatment (median: eight months in patients with high ERCC1 versus 24 months in low ERCC1 expression, hazard ratio (HR) 2.95 (95% confidence interval (CI) 1.4–6.2), P=0.004). Multivariate analysis confirmed that high ERCC1 expression was a predictive factor for poor prognosis in platinum treated patients (HR 2.2, 95% CI 1.0–4.5, P=0.038). Our findings suggest that ERCC1 expression is the first factor for predicting survival in ACC patients treated with platinum-based chemotherapy.

Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy

2015 ◽  
Vol 67 (3) ◽  
pp. 338-347 ◽  
Author(s):  
Claudia Maria Hattinger ◽  
Francesca Michelacci ◽  
Federica Sella ◽  
Giovanna Magagnoli ◽  
Stefania Benini ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Protein Expression ◽  
Excision Repair ◽  
Complementation Group ◽  
High Grade ◽  
Metastatic Osteosarcoma ◽  
Group 1
Sign in / Sign up

Export Citation Format

Share Document